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ABSTRACT
The purpose of this study was to determine the effects of chronic estrogen
supplementation on NPY neurotransmission in gastrocnemius first-order arterioles (G1A)
of adult female rats. Female rats (4 mo; n = 30) were ovariectomized (OVX) with a
subset (n = 15) receiving an estrogen pellet (OVE; 17β-estradiol (4μg / day)). Following
conclusion of the treatment phase (8 weeks), red G1A were excised, placed in a
physiological saline solution (PSS) bath, and cannulated with micropipettes connected to
albumin reservoirs. A sampling port was placed immediately below the vessel to assess
NPY overflow. The contralateral red G1A was homogenized in PSS for dipeptidyl
peptidase IV (DPPIV) assay. NPY-mediated vasoconstriction via a Y1-agonist,
[Leu31Pro34]NPY, decreased vessel diameter 44.54 ± 3.95% as compared to baseline;
however, there were no group differences in EC50 (OVE: -8.97 ± 0.36; OVX: -8.72 ±
0.20 log M [Leu31Pro34]NPY) or slope (OVE: -1.37 ± 0.38; OVX: -1.64 ± 0.31 %
baseline / log M [Leu31Pro34]NPY). NPY did not potentiate norepinephrine-mediated
vasoconstriction. NPY overflow experienced a slight increase following field
stimulation, and significantly increased (p < 0.05) over control conditions in the presence
of a DPPIV inhibitor (diprotin A). Estrogen status did not affect DPPIV activity. These
data suggest that NPY can induce a moderate decrease in vessel diameter in skeletal
muscle G1A, and DPPIV is active in mitigating NPY overflow in young adult female
rats. Chronic estrogen supplementation did not influence NPY vasoconstriction,
overflow, or its enzymatic breakdown in skeletal muscle G1A.
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INTRODUCTION
The regulation of blood flow throughout the body is a process that utilizes local
and systemic control mechanisms to ensure that metabolic demands are fulfilled while, at
the same time, maintaining adequate blood pressure for the greater cardiovascular
system. The local control mechanisms of the vasculature consist of a finely tuned
network of chemical processes that originate primarily from within the endothelium,
whereas the systemic control lies within sympathetic innervations in addition to the
endocrine stimuli in the blood. It is a coordinated response between these loci that
produces constant change in blood vessel diameter, which ensures normal function of
biological processes.
The neural control of blood vessel diameter is attributed to the sympathetic
nervous system. These sympathetic nerves arise from the spinal cord as pre-junctional
nerves, synapse to the post-junctional nerve, and traverse across the blood vessel’s
adventitial surface (Guyton & Hall, 2006). Norepinephrine, adenosine triphosphate
(ATP), and neuropeptide Y (NPY) are the primary neurotransmitters responsible for
propagating the neural response from the sympathetic end terminal to the blood vessel.
These neurotransmitters work in a coordinated fashion, each possessing their own degree
of direct influence on the vessel while also modulating other chemical processes
simultaneously. There is evidence to suggest that sympathetic neurotransmission is not
uniform between the sexes (Jackson, Milne, Noble, & Shoemaker, 2005a, 2005b).
Females may possess more, or less, responsiveness to specific chemical mediators within
the sympathetic triad. These differences can be observed in neurotransmitter release,
receptor function/activity, enzymatic activity, and cellular signaling.
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Neuropeptide Y is found in vascular beds throughout the body, and it possesses
many of the same direct and indirect actions as norepinephrine and ATP. Neuropeptide
Y is a potent vasoconstrictor, yet its role in vasoconstriction may be more relevant in
small caliber vessels such as arterioles (Joshua, 1991; Kim, Duran, Kobayashi, Daniels,
& Duran, 1994; Macho, Perez, Huidobro-Toro, & Domenech, 1989; Pernow, 1989) as
opposed to large conduit vessels, which exhibit little to no responsiveness to NPY
(Grundemar & Hogestatt, 1992; Tsurumaki, Honglan, & Higuchi, 2003; Wahlestedt,
Yanaihara, & Hakanson, 1986). Neuropeptide Y can elicit a 2- to 4-fold potentiation of
vasoconstriction to norepinephrine in most vascular beds (Abel & Han, 1989; Prieto,
Benedito, Simonsen, & Nyborg, 1991). It is plausible that this mechanism is involved
during low levels of sympathetic activation as potentiation is observed at nanomolar
concentrations of both NPY and norepinephrine. Neuropeptide Y autoregulates its own
release as well as modulates the release of norepinephrine and ATP (Lundberg & Stjarne,
1984; Ohhashi & Jacobowitz, 1983; Stjarne, Lundberg, & Astrand, 1986), thus NPY is
intimately involved in all facets of sympathetic vasocontrol.
The beneficial effects of 17β-estradiol, herein referred to as estrogen, have been
well documented with the most notable being the activation of endothelial nitric oxide
synthase (eNOS) (Moriarty, Kim, & Bender, 2006). This provides a secondary stimulus
for the generation of nitric oxide, the first being luminal shear stress, which is a direct
stimulus for vasodilation. Estrogen modulates sympathetic neurite branching in uterine
arteries, possibly due to direct actions on nerve growth factors such as brain derived
neurotrophic factor (Krizsan-Agbas, Pedchenko, Hasan, & Smith, 2003). A decrease in
neurite density across the blood vessel would mitigate the degree of sympathetic

2

influence. The cyclical neuritogenesis and neurite degeneration as influenced by estrogen
throughout estrous is an example of how estrogen can impact the resultant magnitude of
sympathetic neurotransmission. A recent study found postmenopausal women to have
higher concentrations of NPY within uterine arteries as compared to premenopausal
women (Di Carlo, et al., 2007). This information along with increased protease activity
in young females as compared to males (Jackson, et al., 2005b) suggests that estrogen
may play a role in sympathetic neurotransmission, but the full scope of that role remains
to be fully understood.
There is a disparity in the vascular responses to NPY between males and females
with much of the differences attributed to total NPY content, the type of receptor
expressed, and the activity of enzymes that breakdown NPY (Jackson, et al., 2005a,
2005b). Estrogen may be the underlying mechanism in the increase in NPY content in
the reproductive vasculature following menopause, and it may be responsible, in part, to
the differences observed in NPY neurotransmission in large conduit vessels. There is a
paucity of literature examining the actions of NPY in sympathetic neurotransmission of
skeletal muscle, small caliber resistance vessels. This level of the vasculature is of
greater significance as it is at this level where the majority of regulatory control occurs
with respect to systemic blood pressure (Segal, 2005). The resistance vasculature is also
affected in pathophysiological conditions such as peripheral arterial disease and diabetes
(Cersosimo & DeFronzo, 2006), therefore the need for further study is clearly indicated.
The specific aim of the proposed study is to examine the influence of estrogen on
NPY release, post-junctional receptor activity, and enzymatic activity of proteases that
degrade NPY. It is my belief that estrogen will mitigate the overall stimulus of NPY in
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the resistance vessels. These results may explain a portion of the vascular changes that
occur in response to the disruption of normal estrogen concentrations during menopause
and beyond. In addition, these results may elucidate yet another mechanism of estrogen’s
cardioprotective function in the vasculature.
Primary Aim: To determine the effects of chronic estrogen supplementation on NPY
release, receptor activity, and breakdown in gastrocnemius first-order arterioles.
Hypotheses
1. NPY release following field stimulation will decrease with chronic estrogen
supplementation in gastrocnemius first-order arterioles.
2. Chronic estrogen supplementation will decrease the amount of vasoconstriction in
response to NPY administration in gastrocnemius first-order arterioles.
3. Chronic estrogen supplementation will decrease the extent at which NPY potentiates
adrenergic vasoconstriction in gastrocnemius first-order arterioles.
4. DPPIV activity will be greater in gastrocnemius first-order arterioles with chronic
estrogen supplementation.
Limitations
1. Arteriole size was not included in the statistical analysis of the DPPIV activity assay
due to the sample medium’s interference with the kit components of the protein assay.
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REVIEW OF LITERATURE
Neuropeptide Y (NPY) is a 36-amino acid polypeptide that is widely expressed
throughout the central and peripheral nervous systems. Neuropeptide Y exhibits
neuroendocrine function in the pituitary and hypothalamus, possessing various levels of
influence on releasing hormones involved in satiety, reproduction, and development.
Neuropeptide Y also acts as a neurotransmitter in central and peripheral nervous tissue
owing to its functional duality in the body, and it is in this latter role that NPY exerts a
level of influence over vascular regulation.
NPY Structure and Synthesis
A family of polypeptides characterized by a tyrosine residue at the C-terminus
was discovered in 1980 by Tatemoto and Mutt (1980). Peptide YY and peptide histidine
isoleucine were observed in the gut region with putative influence on pancreatic secretion
(Jensen, Tatemoto, Mutt, Lemp, & Gardner, 1981; Tatemoto, 1982a). A polypeptide was
also observed in the brain, but it was thought to be peptide YY due to its characteristic Nand C-terminus tyrosine residues (Tatemoto, 1982a). However, while sharing substantial
sequence homology with peptide YY, the brain polypeptide was not identical (Tatemoto,
1982b). Thus, the brain polypeptide was designated as a novel neuropeptide,
neuropeptide Y (Tatemoto, Carlquist, & Mutt, 1982). In addition to sequence homology
with peptide YY (67%), NPY is structurally similar to another gut peptide, pancreatic
polypeptide (50%) (see Table 1) (Takeuchi & Yamada, 1985; Tatemoto, 1982b;
Tatemoto, et al., 1988). The gene that encodes NPY is found on chromosome 7 (7pterq22) (Takeuchi, et al., 1986), while the gene for pancreatic polypeptide is located on
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chromosome 17. The difference in chromosomal location for peptides of the same family
could be attributed to evolutionary genetic translocation (Takeuchi, et al., 1986).
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Table 1
Amino Acid Sequences of NPY, Peptide YY, and Pancreatic Polypeptide
Peptide

Amino Acid Sequence

NPY

Tyr-Pro-Ser-Lys-Pro-Asp-Asn-Pro-Gly-Glu-Asp-Ala-ProAla-GluAsp-Met-Ala-Arg-Tyr-Tyr-Ser-Ala-Leu-Arg-His-Tyr-IleAsn-LeuIle-Thr-Arg-Gln-Arg-Tyr-NH2

Peptide YY

Tyr-Pro-Ile-Lys-Pro-Glu-Ala-Pro-Gly-Glu-Asp-Ala-SerPro-GluGlu-Leu-Asn-Arg-Tyr-Tyr-Ala-Ser-Leu-Arg-His-Tyr-LeuAsnLeu-Val-Thr-Arg-Gln-Arg-Tyr-NH2

Pancreatic Polypeptide

Ala-Pro-Leu-Glu-Pro-Val-Tyr-Pro-Gly-Asp-Asn-Ala-ThrProGlu-Gln-Met-Ala-Gln-Tyr-Ala-Ala-Asp-Leu-Arg-Arg-TyrIleAsn-Met-Leu-Thr-Arg-Pro-Arg-Tyr-NH2

Note. Amino acids underlined are in the same sequential position as the corresponding
amino acid in NPY; amino acids in bold are unique to that specific peptide.
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Transcription and translation. Prepro-NPY consists of a 97 amino-acid chain
with a 28 amino acid signal peptide, followed by the expressed 36 amino acid peptide
(NPY) (Minth, Bloom, Polak, & Dixon, 1984). A polymorphism in the signal peptide
(Leu7Pro) may influence translocation of prepro-NPY to the endoplasmic reticulum,
post-translational modifications, and the expression of mature NPY (Kallio, et al., 2001).
This polymorphism has been linked to hypercholesteremia and atherosclerosis in some
populations (Karvonen, et al., 2000; Niskanen, et al., 2000). Kaipio, Kallio, and Pesonen
(2009) observed premature apoptosis and decreased angiogenesis in response to vascular
endothelial growth factor in human umbilical vascular endothelial cells that possessed
this polymorphism, which would be an indicator of endothelial dysfunction. However,
this polymorphism has also been associated with decreased free fatty acids and insulin
concentrations during exercise (Kallio, et al., 2001). While the increase in NPY appears
to accompany this polymorphism, it is difficult to surmise a negative or positive
relationship in cardiovascular profile. The amino acid chain that follows expressed NPY,
C-flanking Peptide Of Neuropeptide Y (CPON), may have physiological function (Allen,
Polak, & Bloom, 1985). Immunoreactivity to CPON was detected in the heart, adrenal
glands, and kidney. In the brain, CPON immunoreactivity was detected in the
hypothalamus, striatum, hippocampus, frontal cortex, and the brain stem. While CPON
immunoreactivity appears to mirror NPY concentrations in certain tissues, a
physiologically relevant function for CPON has not been identified.
NPY Locations
Brain. NPY is the most abundant peptide of the brain (Adrian, et al., 1983) with
NPY immunoreactivity detected at greatest concentrations in the deep layers of the brain
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and brain stem (Y. S. Allen, et al., 1983; Sawchenko, et al., 1985). In the limbic system,
NPY immunoreactivity was present in the arcuate and paraventricular nuclei of the
hypothalamus (Lundberg, Terenius, Hokfelt, & Tatemoto, 1984), the pineal gland, and
the pituitary gland (Chronwall, et al., 1985). Neuropeptide Y immunoreactivity was also
found in the hippocampus and the dentate gyrus. In the brain stem, cell bodies with NPY
immunoreactivity were observed in the periaqueductal gray region, and to a lesser extent,
the locus coeruleus, the nuclei of the tractus solitarius (Lundberg, Terenius, et al., 1984),
and the superficial laminae of the trigeminal nucleus. In the medulla oblongata, NPY
immunoreactivity was abundant in the raphe nuclei of the reticular formation and the
dorsal motor nucleus of the vagus (Hokfelt, et al., 1983). In the basal ganglia, high
concentrations of NPY immunoreactivity were found in the caudate nucleus and putamen
(Adrian, et al., 1983). Hypothalamic NPY is released at circadian intervals with the
greatest release occurring in the morning (7:00am) followed by a gradual decline
throughout the day (Nicholson, et al., 1983).
Neuropeptide Y can be found in NPYergic (Bai, et al., 1985), adrenergic, and
GABAergic (Hendry, et al., 1984) neurons within the brain. The NPYergic neurons
arising from the arcuate nucleus contain a rich supply of NPY (Bai, et al., 1985).
Removal of the arcuate nucleus resulted in a steep decline in NPY immunoreactivity
suggesting that this is the primary origin of NPY immunoreactivity found in the brain.
Neuropeptide Y is transported in A1-3 (Bai, et al., 1985; Everitt, et al., 1984), A4-8, A10,
A12, A14-15 (Everitt, et al., 1984), and C1-3 (Everitt, et al., 1984; Sawchenko, et al., 1985)
adrenergic neurons. Neuropeptide Y immunoreactivity co-localizes with norepinephrine
(A1-2, A4, A6) and epinephrine (C1-2) in adrenergic neurons, however trace amounts of
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NPY immunoreactivity have been observed in the absence of catecholamines (A5, A7, A810,

A12, A14-15) (Everitt, et al., 1984). Since GABAergic (λ-aminobutyric acid) neurons

participate in inhibitory stimuli, NPY found in GABAergic neurons may play a role in
facilitating the actions of this neuronal type (Hendry, et al., 1984).
In the brain, NPY exhibits neuroendocrine behavior by modulating the release of
hormones involved in protein synthesis, cell growth, reproduction, and eating behavior
(Clark, Kalra, Crowley, & Kalra, 1984; J. K. McDonald, Lumpkin, Samson, & McCann,
1985). NPY also has cerebrovascular actions, however this will be discussed in
subsequent sections and will receive no further mention here. Neuropeptide Y is a potent
stimulus for the feeding response in animal models. Intraventricular injection of NPY
resulted in an increased feeding response, and this response was 3-fold greater than the
response elicited by pancreatic polypeptide (Clark, et al., 1984). In a separate study by
Stanley, Daniel, Chin, and Leibowitz (1985), carbohydrate was the preferred
macronutrient following intraventricular injection with smaller differences between
control and experimental trials in fat and protein consumption.
Neuropeptide Y possesses stimulatory effects on pituitary release of luteinizing
hormone (Kalra & Crowley, 1984; Kerkerian, Guy, Lefevre, & Pelletier, 1985; J. K.
McDonald, et al., 1985). In ovariectomized rats with estrogen/progesterone
supplementation, intraventricular injection of low concentrations of NPY (0.1-2.0μg)
resulted in a marked increase in luteinizing hormone concentrations 10 minutes following
application (Kalra & Crowley, 1984). Luteinizing hormone-releasing hormone
concentrations tend to rise and fall in concert with NPY concentrations, suggesting a
modulatory effect for NPY on luteinizing hormone-releasing hormone (Crowley, Tessel,
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O'Donohue, Adler, & Kalra, 1985). Progesterone administration causes a substantial, yet
transient, increase in NPY and luteinizing hormone-releasing hormone within the median
eminence followed by a gradual decline with a concurrent rise in luteinizing hormone
concentrations (Crowley, et al., 1985; Kalra & Crowley, 1984). This suggests that NPY
release within the hypothalamus is sensitive to progesterone, and that NPY may possibly
modulate the effects of luteinizing hormone-releasing hormone and subsequent
luteinizing hormone release (Crowley, et al., 1985). Neuropeptide Y may act directly on
the anterior pituitary to stimulate the release of luteinizing hormone and folliclestimulating hormone (FSH) (J. K. McDonald, et al., 1985), however the significance of
this mechanism in vivo is unknown. Progressively larger concentrations of NPY (2-5μg)
depressed circulating concentrations of growth hormone (GH) (J. K. McDonald, et al.,
1985).
Adrenal gland. Neuropeptide Y is found in the adrenal glands of many animals
with the greatest proportion found in the adrenal medulla (Varndell, Polak, Allen,
Terenghi, & Bloom, 1984). There is considerable variability across species in adrenal
NPY content with some animals such as mice expressing significant amounts
(1244pM/g) and other animals such as dogs expressing very little (68pM/g) (Allen,
Adrian, Polak, & Bloom, 1983). In the adrenal cortex, NPY immunoreactivity exists in
the varicose nerve fibers that span the zona reticularis and the subcapsular cortical area
(Varndell, et al., 1984). In the adrenal medulla, NPY co-localizes with norepinephrine,
but not epinephrine, in small (90-120nm) chromaffin granules.
Peripheral vasculature and smooth muscle. Neuropeptide Y is widely
expressed in perivascular nerve fibers that form plexuses across blood vessels (Grasby,
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Morris, & Segal, 1999) and terminate at the adventitial-tunica media border (Fleming,
Gibbins, Morris, & Gannon, 1989). Neuropeptide Y or NPY immunoreactivity has been
detected in the gut (Ekblad, Ekelund, Graffner, Hakanson, & Sundler, 1985; Lundberg,
Terenius, Hokfelt, & Goldstein, 1983; Sundler, Moghimzadeh, Hakanson, Ekelund, &
Emson, 1983), ear (Hieble, Ruffolo, & Daly, 1988), uvea (Terenghi, et al., 1983),
throughout the female and male reproductive anatomy (Lundberg, et al., 1983; Owman,
et al., 1986; Stjernquist, et al., 1983), kidney (Ballesta, Polak, Allen, & Bloom, 1984),
respiratory tract (Uddman, Sundler, & Emson, 1984), heart (Gu, et al., 1984), thyroid
gland (Grunditz, Hakanson, Rerup, Sundler, & Uddman, 1984), spleen (Lundberg, et al.,
1983), omentum (Edvinsson, et al., 1985), skin (Lundberg, et al., 1983), and sweat glands
(Tainio, Vaalasti, & Rechardt, 1986). Neuropeptide Y is found in a variety of
nonvascular smooth muscle such as vas deferens (Fried, Terenius, Hokfelt, & Goldstein,
1985; Lundberg, et al., 1983), intestine (Sundler, et al., 1983), lung (Lundberg, et al.,
1983), and eye (J. M. Allen, G. P. McGregor, et al., 1983).
Other nonvascular sites. Neuropeptide Y is also found in the submucosal layers
of the stomach (Ekblad, et al., 1985), prostate gland, submandibular gland (Lundberg, et
al., 1983), fallopian tube, uterus (Owman, et al., 1986), and thyroid gland (Grunditz, et
al., 1984).
NPY Storage and Transport
Neuropeptide Y is co-stored along with norepinephrine in the large dense-cored
vesicles (80-120nm) of adrenergic neurons (Ekblad, et al., 1984; Fleming, et al., 1989;
Fried, Terenius, et al., 1985; Grasby, et al., 1999; Lundberg, et al., 1983; Tainio, et al.,
1986). A 50:1 ratio of norepinephrine to NPY exists in these large vesicles, while no
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NPY immunoreactivity is observed in the small-type (50nm) vesicles (Fried, Lundberg,
& Theodorsson-Norheim, 1985; Fried, Terenius, et al., 1985). Unlike norepinephrine, in
which neurons have the enzymatic capability (tyrosine hydroxylase, dopamine βhydroxylase) for synthesis within the sympathetic end terminal (Fried, Lundberg, et al.,
1985), NPY depends (9mm/hour) on axonal transport for reconstitution. Therefore, the
discrepancy in norepinephrine:NPY ratios can become more pronounced in distal
sympathetic end terminals (Fried, Lundberg, et al., 1985). Reserpine experiments, which
deplete the neurotransmitter content of sympathetic end terminals, produced a rebound
supracompensation of norepinephrine and dopamine β-hydroxylase (160% and 140%,
resp.) that was observed four days following reserpine administration (Dahlstrom, et al.,
1986). In comparison, NPY experienced a slight decrease over time in addition to the
acute decline (50%) that occurred following reserpine treatment (Dahlstrom, et al., 1986;
Morris, Murphy, Furness, & Costa, 1986). The disparity in reconstitution between NPY
and norepinephrine supports the putative differences in neurotransmitter synthesis and
transport.
Neuropeptide Y is also stored and released from chromaffin granules within the
adrenal medulla, thus participating in the systemic pressor response along with
norepinephrine and epinephrine (Lundberg, Fried, Pernow, & Theodorsson-Norheim,
1986). Upon adrenal activation, systemic concentrations of NPY can increase 2-fold over
normal resting concentrations, while norepinephrine and epinephrine experience a greater
increase in circulating concentrations (Lundberg, Fried, Pernow, & TheodorssonNorheim, 1986). The larger increase in circulating catecholamines is, in part, attributed
to larger stored concentrations within the adrenal medulla. In the adrenal medulla of the

13

cat, NPY storage is 1:2000 to norepinephrine and 1:1500 to epinephrine (Lundberg,
Fried, Pernow, & Theodorsson-Norheim, 1986). However, NPY remains elevated in the
circulation for a longer duration as compared to norepinephrine and epinephrine
following a pressor stimulus.
NPY Release from Peripheral Sympathetic Nerves
Action potentials propagated from the proximal post-junctional nerve result in
fusion of the neurotransmitter-containing vesicles to the neural membrane at the synapse
and neurotransmitter release via exocytosis. As NPY is co-stored with norepinephrine in
large dense-cored vesicles, NPY is also co-released with norepinephrine during the neural
action potential (Lundberg, Martinsson, et al., 1985; Pernow, 1988).
NPY Receptors and Vascular Actions
There are six known receptors for NPY, Y1-6 (Balasubramaniam, 1997), although
only a few possess vascular actions (Wahlestedt, et al., 1990). In vascular smooth
muscle, the Y1 receptor is located at the cell membrane where it binds with complete
NPY(1-36). The Y1 receptor belongs to a class of G-protein coupled receptors, whereby it
creates the cellular conditions for vasoconstriction. The Y2 receptor is primarily located
on the sympathetic end terminal although it can be found on vascular smooth muscle in
some vascular beds (Tessel, Miller, Misse, Dong, & Doughty, 1993a, 1993b). However,
unlike the Y1 receptor, the Y2 receptor is capable of binding C-truncated fragments of
NPY in addition to binding the full-length peptide.
Y1 receptor mechanisms. The binding of NPY(1-36) to the Y1 receptor results in
the dissociation of an inhibitory G protein, Gi, which inhibits adenylate cyclase activity
and subsequent cyclic AMP (cAMP) production (Lobaugh & Blackshear, 1990; Reynolds
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& Yokota, 1988). Pertussis toxin, which blocks Gi signaling, abrogates the decrease in
adenylate cyclase activity and subsequent vasoconstriction following NPY administration
(Andriantsitohaina, Andre, & Stoclet, 1990; Morris, 1991). The fact that pertussis toxin
does not effect the contractile mechanisms of vascular smooth muscle suggests that Gi
signaling is a primary mechanism behind NPY vasoconstriction (Morris, 1991). While
pertussis toxin virtually blocks vasoconstriction in small arterioles (Andriantsitohaina, et
al., 1990), there is still vasoconstriction to NPY in larger vessels (Morris, 1991) even in
the presence of pertussis toxin. This would suggest that other cellular signaling
mechanisms are involved following activation of the Y1 receptor. Indeed, an increase in
intracellular calcium follows Y1 activation in many vascular beds (Oshita, Kigoshi, &
Muramatsu, 1989; Pernow & Lundberg, 1986; Shigeri & Fujimoto, 1993; Tessel, et al.,
1993b; Xiong, Bolzon, & Cheung, 1993). Nifedipine, an L-type calcium channel
blocker, is successful in blocking a portion of vasoconstriction caused through Y1
activation (Tessel, et al., 1993b). The L-type calcium channel is voltage sensitive, and is
the primary mechanism behind calcium influx in response to cell depolarization of
vascular smooth muscle. In cerebral and internal carotid arteries, NPY increased vascular
smooth muscle membrane potential 15mV above baseline values (Abel & Han, 1989).
Neild (1987) observed depolarization (+16mV over baseline) of rat tail artery similar to
the values observed by Abel and Han (1989). The onset of depolarization was slow (5-10
minutes post-application), and a correlation was observed between vasoconstriction and
depolarization. The depolarizing effect of NPY is independent of endothelial influences
as endothelium removal did not alter the increases in membrane potential following NPY
administration (Gustafsson & Nilsson, 1990).
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Vascular smooth muscle contraction can also be influenced by the release of
calcium from intracellular storage sites. The second messenger that is most associated
with the release of intracellular calcium stores is inositol 1,4,5-triphosphate (IP3).
Neurotransmitters that utilize IP3 as a second messenger (e.g. norepinephrine) are capable
of producing substantial vasoconstriction. In porcine aortic vascular smooth muscle,
NPY administration did not directly increase IP, IP2, or IP3 concentrations, but NPY did
potentiate angiotensin II-mediated vasoconstriction (Lobaugh & Blackshear, 1990). NPY
also increased norepinephrine-stimulated IP3 production in rat tail artery (Duckles &
Buxton, 1994). The ability of NPY to stimulate or influence the upstream enzyme for IP3
production, phospholipase C, is equivocal. Lobaugh and Blackshear (1990) concluded
that phospholipase C activity was unaffected by NPY administration in cultured porcine
aortic vascular smooth muscle cells. The absence of changes in phospholipase C activity
and IP3 production was unexpected as NPY increased intracellular calcium in an
environment void of extracellular calcium. This would suggest an internal store of
calcium susceptible to NPY activation. Shigeri, Nakajima, and Fujimoto (1995) observed
nonsignificant increases in IP3 production in cultured porcine aortic smooth muscle cells.
However, their experiments included inhibitors for the various phospholipase C isoforms
to determine what, if any, isoforms were susceptible to NPY stimulation. Experiments
that inhibited phospholipase C-β abolished the increase in intracellular calcium following
NPY administration. Therefore, NPY likely potentiates IP3 production via activation of
phospholipase C-β. While a subsequent increase in IP3 production following NPY
administration is not substantial, it would appear that this pathway is involved in NPYmediated vasoconstriction via release of calcium from intracellular stores.
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ATP-activated potassium channel currents decreased by 43% with NPY
administration in rabbit mesenteric artery (Bonev & Nelson, 1996). These channels are
inhibited by protein kinase C , which is a downstream signal of phospholipase C. Bonev
and Nelson (1996) noted increases in ATP-activated potassium channel currents
following inhibition of protein kinase C and phospholipase C activity during NPY
stimulation, which would support the notion of phospholipase C activation following Y1
stimulation. The conglomeration of active second messengers in some tissues could be
the result of heterodimeric complexes comprised of multiple receptor subtypes (Pons, et
al., 2008). These complexes consist of Y1 and Y5 subtypes, and have been classified as
Gi/o subtype receptors. This heterodimeric complex inhibits adenylate cyclase activity
and stimulates phospholipase C activity, which inhibits (cAMP (protein kinase A)) and
promotes (IP3, diacylglycerol (protein kinase C)) the respective second messengers
associated with each enzyme. Certainly, there is still debate as to the functional
significance of such multi-receptor complexes in producing meaningful concentrations of
IP3. Regardless, the Y1 receptor is recognized as the post-junctional receptor for NPY
responsible for stimulating vasoconstriction via activation of L-type and R-type (Pons, et
al., 2008) calcium channels.
Y2 receptor mechanisms. The Y2 receptor is primarily located on the
sympathetic end terminal where it acts to inhibit NPY release in addition to the inhibition
of adrenergic and purinergic neurotransmitters (Lundberg, Torssell, et al., 1985). There
are vascular beds, however, where Y2 receptors are expressed on the vascular smooth
muscle (McAuley & Westfall, 1992). As a pre-junctional receptor, Y2 is a Gi-protein
coupled receptor where it exerts influence on cellular signaling by inhibiting both
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adenylate cyclase activity and N-type calcium channels (R. L. McDonald, Vaughan,
Beck-Sickinger, & Peers, 1995; Wahlestedt, et al., 1990). Y2 receptors have a high
affinity for the full length peptide (NPY(1-36)) in addition to the cleavage products, NPY(236)

and NPY(3-36), of aminopeptidase P and dipeptidyl peptidase IV, respectively. Y2

receptors also exhibit binding affinity for the full-length and truncated fragments of
peptide YY and pancreatic polypeptide (Wahlestedt, et al., 1990).
Vascular actions. Neuropeptide Y stimulates vasoconstriction in many vascular
beds through Y1 and Y2 receptor mechanisms previously discussed. In the cat spleen,
NPY caused a dose-dependent increase in perfusion pressure (Lundberg, Anggard,
Theodorsson-Norheim, & Pernow, 1984; Lundberg, Fried, Pernow, TheodorssonNorheim, & Anggard, 1986). The vascular response had a slow onset with the increase in
perfusion pressure manifesting 2-5 minutes following NPY administration. The
vasoconstriction to NPY can linger over time. In this tissue, the increase in perfusion
pressure persisted for 10 minutes following the initial increase (Lundberg, Anggard, et
al., 1984). Furthermore, the increase in perfusion pressure was impervious to α- or βadrenoceptor blockade. In porcine spleen, an increase in NPY-like immunoreactivity
following transmural stimulation occurred 2-5 minutes post-stimulation, and the
concentration was 4-5 times greater with larger frequencies (20Hz) as compared to small
frequencies (2Hz) (Lundberg, Rudehill, Sollevi, Theodorsson-Norheim, & Hamberger,
1986). In rabbit cerebral and internal carotid arteries, NPY produced vasoconstriction
that was 21% and 79% to vasoconstriction produced by histamine and norepinephrine
(Abel & Han, 1989). Minute vasoconstriction following NPY administration was
observed in internal maxillary artery (Lacroix, Stjarne, Anggard, & Lundberg, 1988). In
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human studies, forearm blood flow decreased during NPY administration in a dosedependent fashion. A similar lag in response was observed in these studies (2 minutes
between time of administration and changes in blow flow) as was the long-lasting effect
(~15 minutes of vasoconstriction) (Clarke, et al., 1991). In human saphenous vein, NPY
produced a small amount of vasoconstriction (~ 28% of maximum contraction) (Luu,
Chester, O'Neil, Tadjkarimi, & Yacoub, 1992). Neuropeptide Y, along with
norepinephrine, is an important neurotransmitter involved in stimulating reflex
vasoconstrictor mechanisms in humans (Stephens, Saad, Bennett, Kosiba, & Johnson,
2004). During whole body cooling, Y1 receptor blockade significantly decreased reflex
vasoconstriction, while Y1 plus α-adrenoceptor blockade abrogated reflex
vasoconstriction entirely.
In some vascular beds, NPY fails to cause direct vasoconstriction, but it can
potentiate the vasoconstriction caused by other neurotransmitters. In rat tail artery, NPY
had no direct vasoconstriction, but did potentiate vasoconstriction to transmural nerve
stimulation (Vu, Budai, & Duckles, 1989). Interestingly, NPY did not potentiate
vasoconstriction to norepinephrine in this vessel, although it did increase the rate of
contraction to norepinephrine as well as transmural nerve stimulation. In rabbit cerebral
and internal carotid arteries, NPY was capable of potentiating vasoconstriction to
norepinephrine with no change in maximum vasoconstriction (Abel & Han, 1989). In the
perfused mesenteric vascular bed, NPY administration produced little vasoconstriction,
but potentiated vasoconstriction to norepinephrine and α,β-methylene ATP (Han, et al.,
1998). It was concluded that NPY is involved in 30% of the vasoconstriction to
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sympathetic nerve stimulation at this level of the vasculature when taking into account
the potentiation of vasoconstriction to other neurotransmitters.
The ability of NPY to stimulate vasoconstriction appears to increase as vessel
diameter decreases, thus becoming more relevant at the level of the resistance
vasculature. In rabbit tenuissimus muscle arterioles, NPY was 10-fold more potent on a
molar basis as compared to norepinephrine (Pernow, Ohlen, Hokfelt, Nilsson, &
Lundberg, 1987). The magnitude of vasoconstriction was identical (65% and 64%)
between NPY and norepinephrine, respectively, in these vessels. As was seen in the
perfused spleen, vasoconstriction was long-lasting with constriction observed five
minutes following application. There was also a 2-3 minute lag in response between the
initial time of administration and the first signs of vasoconstriction. In rat cremaster
muscle, NPY-mediated vasoconstriction was approximately 61%, 54%, and 18% of
resting diameter in first-, second-, and third-order arterioles (Joshua, 1991). In hamster
cheek pouch microvessels, NPY decreased resting vessel diameter by 50% with a lag
time of 5 minutes between administration and response, and a long-lasting response up to
20 minutes (Kim, et al., 1994). Neuropeptide Y-mediated vasoconstriction was
unaffected by α-adrenoceptor blockade. In human small arteries, NPY was capable of
eliciting vasoconstriction equal in magnitude to that of norepinephrine (Pernow, 1989).
While the effects of NPY in skeletal muscle arterioles are unknown, the present literature
suggests a larger overall response to NPY at the arteriole level.
Proteolytic Enzymes
Dipeptidyl peptidase IV. Dipeptidyl peptidase IV is a proteolytic enzyme that
cleaves off the tyrosine-proline residue yielding a C-truncated product, NPY(3-36)
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(Mentlein, Dahms, Grandt, & Kruger, 1993; Mentlein & Roos, 1996). Dipeptidyl
peptidase IV has been identified in human umbilical vascular endothelial cells
(Zukowska-Grojec, et al., 1998) and it also exists in a soluble form (CD26) (Durinx, et
al., 2000). Dipeptidyl peptidase IV activity plays a significant role in modulating NPY
neurotransmission in females as inhibition results in a significant decrease in blood flow
and vascular conductance in external iliac arteries (Jackson, et al., 2005b). Similar
results were observed in vasoconstriction experiments of the rat tail artery using
peptidase inhibitors (Glenn, Krause, & Duckles, 1997). Alternative pathways such as
angiogenesis are directly influenced by dipeptidyl peptidase IV activity as NPY-mediated
angiogenesis depends on the activation of Y2 receptors, which have binding affinity for
C-truncated fragments of NPY. While dipeptidyl peptidase IV appears to possess a
greater role in female NPY neurotransmission, the mechanisms that underlie this larger
role have yet to be elucidated.
Vascular Effects of Estrogen
Estrogen has many direct and indirect effects on local blood flow and blood
pressure with most effects pertaining to vessel dilation. The primary mechanism is
activation of endothelial nitric oxide synthase, which produces nitric oxide (cyclic GMP)
resulting in vasodilation (Moriarty, et al., 2006). Estrogen also ameliorates the
accumulation of free radicals through increased activity of dismutases and peroxidases
(Duckles, Krause, Stirone, & Procaccio, 2006; Vina, Borras, Gomez-Cabrera, & Orr,
2006). In addition to the vasodilating effects, estrogen attenuates endothelium-dependent
mechanisms involved in vasoconstriction. Cyclooxygenase products such as
prostaglandin H that arise from endothelial cells can be depressed in arteries with

21

estrogen (Davidge & Zhang, 1998). Other endothelium-derived vasoconstrictive
products such as endothelin 1 and angiotensin II, through estrogen’s influence on
angiotensin converting enzyme, decrease with estrogen (Miller & Duckles, 2008).
Estrogen receptors (ERα, ERβ) are expressed on adrenergic, cholinergic, and
serotenergic nerves (Vanderhorst, Gustafsson, & Ulfhake, 2005). Removal of estrogen
can lead to increases in circulating norepinephrine concentrations and increases in
vascular resistance (Miller & Duckles, 2008). Estrogen decreases both the expression of
α-adrenergic receptors and the enzymes (tyrosine hydroxylase) responsible for the
production of precursors to norepinephrine (Kaur, Janik, Isaacson, & Callahan, 2007;
Miller & Duckles, 2008). In rat tail artery segments, estrogen supplementation resulted
in decreased force production to norepinephrine (Stice, Eiserich, & Knowlton, 2009).
Krizsan-Agbas, Pedchenko, Hasan, and Smith (2003) concluded that estrogen modulates
sympathetic activity in uterine tissue by influencing the expression of brain derived
neurotrophic factor, which modulates neuritogenesis and neurite degradation. This
modulatory influence was recently extended to vascular tissue with estrogen
supplementation decreasing nerve growth factor expression in extracerebral blood vessels
in addition to the superior cervical ganglia (Kaur, et al., 2007). The effects of estrogen on
NPY neurotransmission in the vasculature have not been determined.
The effects of sex on NPY neurotransmission have received attention in large
conduit vessels. Females possess less Y1 receptor expression and total NPY content in
the gastrocnemius muscle (whole tissue) than their male counterparts (Jackson, et al.,
2005a). Females also experience little change in blood flow to Y1 receptor blockade in
external iliac arteries as compared to males (Jackson, et al., 2005a). A follow-up study
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by this same group found Y2 receptor expression to be greater in the gastrocnemius
muscle of females (Jackson, et al., 2005b). Females had a decrease in vascular
conductance and blood flow during Y2 blockade with a return to baseline levels following
combined Y1-Y2 blockade. In a separate group of females, inhibition of the proteolytic
enzymes that target N-terminal amino acid residues of NPY (Tyr and Tyr-Pro) resulted in
a decrease in blood flow and vascular conductance, which suggests that these enzymes
are intimately involved in the modulation of NPY neurotransmission in females (Jackson,
et al., 2005b). This research lends credence to a sex difference in NPY
neurotransmission, but the underlying mechanism or mechanisms responsible for these
differences cannot be answered with the present data. The work of Glenn, Krause, and
Duckles (1997) suggests that sex steroids, in general, modulate NPY neurotransmission
in females. However, there was more potentiation of vasoconstriction to transmural
nerve stimulation following NPY administration in control females as compared to
ovariectomized animals. This would run counter to what Jackson, Milne, Noble, and
Shoemaker (2005b) observed with the decreased Y1 receptor activity in females as
compared to males. However, Glenn, Krause, and Duckles (1997) did note a greater
inhibition in vasoconstriction to transmural nerve stimulation following Y2 receptor
stimulation in control animals, which is consistent with the greater expression of Y2
receptors observed in females (Jackson, et al., 2005b). A weakness of the Glenn, Krause,
and Duckles (1997) study was the inability to control estrogen concentrations. While
attempts were made to monitor the rat’s estrous cycle, the inherent fluctuation of estrogen
in intact females increases the experimental variability (error). Little research exists
regarding estrogen’s impact on NPY neurotransmission in human subjects. Di Carlo et
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al. (2007) detected increases in total NPY content of uterine arteries from postmenopausal women. While estrogen was not controlled per se, these results would
suggest a possible modulatory role for estrogen with regards to NPY neurotransmission.
Purpose of Study
The purpose of this study is to examine the effects of chronic estrogen
supplementation on NPY release, NPYergic receptor actions, modulation of adrenergic
vasoconstriction, and proteolytic enzymes that act on NPY. It is expected that chronic
estrogen supplementation will decrease NPY release and Y1 receptor-mediated
vasoconstriction. The potentiation effect of NPY on adrenergic vasoconstriction is also
expected to attenuate with chronic estrogen supplementation. Lastly, normally active
proteolytic enzymes that modulate NPY neurotransmission through enzymatic cleavage
of N-terminal amino acid residues will become less active in animals without chronic
estrogen supplementation. The present results may possibly elucidate another
mechanism of estrogen's direct effect on sympathetic neurotransmission via the
modulation of NPY neurotransmission in skeletal muscle arterioles. This would further
substantiate estrogen's crucial role in maintaining normal cardiovascular dynamics within
the peripheral circulation as well as revealing the physiological changes that occur in
skeletal muscle arterioles in the absence of estrogen.
Treatment and Experimental Rationale
Ovariectomy and chronic estrogen supplementation. Estrogen impacts the
cardiovascular system through acute (Moriarty, et al., 2006) and chronic mechanisms
(LeBlanc, et al., 2009; Stice, et al., 2009). Ovariectomy is a means to remove the
variability caused by estrogen, but comparisons to intact animals are fraught with
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potential errors pertaining to the estrous cycle. The estrous cycle of a F344 rat is 4-5
days in duration with estrogen fluctuation ranging from approximately 70pg/ml during
proestrous to concentrations as low as 15-20pg/ml during estrous (Haim, Shakhar,
Rossene, Taylor, & Ben-Eliyahu, 2003). Efforts to 'time' the cycle in this animal model
would be tremendously difficult, if not impossible, due to the variable nature of the
estrous cycle in this particular breed. The only valid experimental alternative is to
control estrogen concentrations by means of a secondary source. The use of estrogen
pellets (Innovative Research of America) to maintain an internally controlled
environment is a popular and convenient method for experimental control for this type of
treatment. While treatment (supplementation) times may vary (Davidge & Zhang, 1998;
Kaur, et al., 2007; LeBlanc, et al., 2009; Robbins, Mebane, Ball, Shaffer, & Ness, 2010;
Stice, et al., 2009; Yao, et al., 2005; Zhang, Stewart, & Davidge, 2000), chronic changes
in the vasculature can be observed within two weeks (Kaur, et al., 2007). Haim et al.
(2003) determined that a daily dose of .27µg/day would result in an estrogen plasma
concentration of 34.6pg/ml, and a daily dose of 1.11 µg /day would results in an estrogen
plasma concentration of 137.8pg/ml in F344 rats. The study by LeBlanc et al. (2009) on
F344 rats used a daily dose of 1.67µg /day, which produced an estrogen plasma
concentration of 41pg/ml. This work was relevant to the proposed project in that it
employed microvessel analyses of arterioles. Most importantly, the dose and length of
time (6-8 weeks) of the study was sufficient in observing not only changes in protein
expression, but also changes in vascular response to agonist/antagonist treatments. In the
proposed study, a dose of .25 mg / 60 days, will be used for the estrogen supplementation
group, which has a delivery rate of 4.17 µg /day. The treatment time will range from no
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earlier than 6 weeks to no later than 8 weeks. The serum estrogen concentrations
(Estradiol EIA kit, Oxford Biomedical, Oxford, MI) and uterine weight will be used to
verify estrogen status for each animal at the time of terminal experiment.
Microvessel preparation. In vitro microvessel preparations provide the means to
study the microvasculature in isolation. This is a form of technical control thereby
limiting confounding elements that are difficult to control otherwise (e.g. systemic
influences). Furthermore, this preparation is one of few viable options for the study of
microvascular contraction and relaxation in this animal model. Flow probes, which are
commonly used to measure blood flow, have yet to be designed for vessels of this size
(100-300μm). Therefore, this apparatus is a viable and effective tool in measuring
microvascular contraction and relaxation. In this study, the amount of contraction will be
determined through measurement of the vessel’s diameter using video calipers (Colorado
Video 307A Horizontal Video Calipers, Boulder, CO), which will be referenced against
baseline diameter measurements. While vessel diameter is the measurable event, this
variable is synonymous with vasoconstriction.
Field stimulation. Neuropeptide Y release to field stimulation typically occurs at
large frequencies (>20Hz), with little to no release observed at small frequencies (220Hz) (Lundberg, Rudehill, et al., 1986). This frequency-dependent characteristic of
NPY could be attributed, in part, to the large, dense-cored vesicles where NPY is stored
(Ekblad, et al., 1984; Fleming, et al., 1989; Fried, Terenius, et al., 1985; Grasby, et al.,
1999; Lundberg, et al., 1983; Tainio, et al., 1986). Therefore, a large frequency (60Hz)
will be utilized in the present study. While this is a large frequency of stimulation,
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instantaneous frequencies that exceed 50Hz have been recorded in sympathetic
vasoconstrictor nerves (Macefield, Wallin, & Vallbo, 1994).
Gastrocnemius first-order arteriole. Two (red and white) gastrocnemius firstorder arterioles are downstream of the gastrocnemius feed artery. The red arteriole
supplies blood to the medial gastrocnemius, which is more oxidative than the lateral
gastrocnemius. Therefore, the red arteriole will be used in this study. As a resistance
vessel, the arteriole expresses a diverse array of adrenergic (Pernow, et al., 1987),
NPYergic (Matsuda, Brumovsky, Kopp, Pedrazzini, & Hokfelt, 2002), and purinergic
(Matsuura, Saino, & Satoh, 2004) receptors making it an ideal vessel for the study of
sympathetic neurotransmission. Furthermore, blood pressure is maintained at the level of
the resistance vasculature, which is capable of accommodating a 100-fold increase in
blood flow during periods of maximal oxygen demand (Segal, 2005).
Joshua (1991) observed increases in first-order arteriole vasoconstriction
following NPY administration by approximately 39%. Macho et al. (1989) concluded
coronary resistance vessels (arterioles) to be highly responsive to NPY with regards to
vasoconstriction while noting little responsiveness in large conduit vessels. Neuropeptide
Y was 250-fold more potent than norepinephrine in these coronary arterioles. While this
research pertained to coronary arterioles, the available literature suggests an inverse
relationship between vessel diameter and vessel responsiveness to NPY. Dipeptidyl
peptidase IV is also more active in the gastrocnemius first-order arteriole as compared to
the femoral artery (unpublished data).
Cumulative concentration response curves. Arteriole vasoconstriction to NPY
has been achieved at nanomolar concentrations (10-11-10-7M) (Joshua, 1991; Kim, et al.,
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1994; Pernow, et al., 1987). Therefore, this concentration range for NPY will be
encompassed in the NPY concentration response curve performed in this proposal (10-1110-5M). The potentiation of norepinephrine vasoconstriction can be elicited at nanomolar
concentrations of NPY (10-9-10-7M) (Abel & Han, 1989; Hieble, et al., 1988; Prieto, et
al., 1991; Small, Bolzon, & Cheung, 1992). The greatest concentration (10-7M) of NPY
associated with potentiation of vasoconstriction to norepinephrine will be used as it is the
most oft reported concentration with measureable effects (Vu, et al., 1989).
Preliminary Data
Neuropeptide Y release has been successfully measured in the gastrocnemius
first-order arteriole using the proposed peptide enzyme immunoassay. Figure 1 is NPY
release during α2-adrenoceptor stimulation and inhibition (n=2). The increase in NPY
release following idozoxan (α2-adrenoceptor antagonist) is consistent with synergistic
effects of adrenergic and NPYergic neurotransmission.
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Figure 1. The effects of α2 -adrenoceptor blockade on NPY release following field
stimulation (n = 2). NPY release was detectable using the proposed peptide enzyme
immunoassay.
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Dipeptidyl peptidase IV has been successfully measured in the gastrocnemius
first-order arteriole using the synthetic substrate, glycyl-L-proline-4-methoxy-2naphthylamide. Figure 2 represents dipeptidyl peptidase IV activity in the femoral artery
and gastrocnemius first-order arteriole (n=16). Dipeptidyl peptidase IV activity is greater
in the arteriole. Figure 3 represents dipeptidyl peptidase IV activity in male and female
gastrocnemius first-order arterioles (n=8).
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Figure 2. DPPIV activity of gastrocnemius firstorder arterioles (G1A: n = 16) and femoral
arteries (FEM: n = 16). DPPIV activity was
assessed using the substrate, glycyl-L-proline-4methoxy-2-naphthylamide. Bars indicate mean ±
S.E.M. * Significant difference from OVX (p <
0.05).
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Figure 3. DPPIV activity of male (n = 8) and
female (n = 8) gastrocnemius first-order arterioles.
Bars indicate mean ± S.E.M..
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METHODS
Animal Model
The Fischer 344 rat (F344) exhibits neutral vascular physiology and is void of
hypertensive or other inherent vascular pathological conditions that would preclude
detailed vascular study (Harlan Laboratories, n.d.). All female F344 rats will be
ovariectomized with 15 rats receiving an estrogen pellet (N=30) (Innovative Research of
America, Sarasota, FL) at the time of ovariectomy in order to maintain experimental
control over systemic estrogen concentrations. Animal behavior, food and water intake,
appearance, and surgical incisions will be monitored for 10 days post-operatively.
Records will be kept regarding surgical comments, animal condition, and drug
administration (name, dose, route of administration). Animals will be housed in 17" X
10" X 7.5" cages. A 75%/25% mixture of hardwood chip/wood pulp bedding will be
used as bedding material. Food and water will be provided ad libitum.
Apparatus and Procedure
Ovariectomy and Pellet (17β-Estradiol) Implantation
Female F344 rats (3-4 months of age) were anesthetized using 40mg/kg IP,
sodium pentobarbital. A ventral midline incision was made in the skin caudal to the
border of the ribs and cephalad to the pubic symphysis. A subcutaneous tunnel was made
lateral to the skin incision and the muscles of the abdominal wall separated to allow
access to the abdominal cavity. Using forceps, the periovarian fat was grasped in order to
lift and exteriorize the ovary. The fallopian tube and the uterine horn distal to the ovary
were clamped and the ovary removed by cutting above the clamped area. Following
removal of the ovary, the uterine horn was returned to the abdomen and the process
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repeated for the second ovary. The skin incision was closed using one or two sutures or
wound clips.
In the chronic estrogen supplementation group, estrogen pellets (.25mg; 60 days)
were delivered subcutaneously immediately following ovariectomy. The pellet was
implanted in the dorsoscapular region just behind the left ear above the shoulder using a
10-gauge trochar.
The rats were treated with a topical antibiotic when necessary to prevent
infection. External sutures were removed 7-10 days following surgery. Animals were
housed for 6-8 weeks following ovariectomy to allow for the chronic vascular adaptations
associated with estrogen to occur (LeBlanc, et al., 2009).
Terminal Experiment
Six to eight weeks post-ovariectomy, the rats were administered a single IP dose
of 0.5-0.8cc of 42.5mg/ml (71mg/kg to 113mg/kg) pentobarbital sodium to induce a deep
plane of anesthesia. Depth of anesthesia was determined by lack of response to toe
pinching. Following induction, arterioles were dissected out and removed. Arterioles
were cannulated with glass pipettes to measure vessel diameter. The process of removing
the arterioles took approximately 20 minutes. Blood (5ml) was collected via cardiac
puncture. Blood samples were centrifuged for 3 minutes, the supernatant removed, and
the serum stored at -80C. Immediately following removal of the vessels, an intracardiac
dose of pentobarbital and a pneumothorax was administered. The uterus was removed,
trimmed of connective tissue, and weighed.
Vessel chamber. Arterioles were isolated in a refrigerated vessel chamber
containing cold (4°C) Krebs-Ringer physiological saline solution (119mM NaCl, 4.7mM
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KCl, 2.5mM CaCl2, 1.2mM MgSO4, 25mM NaHCO3, 1.2mM KH2PO4, 5.5mM glucose,
2mM glycerol) (Pourageaud & De Mey, 1998) bubbled with 30% O2, 10% CO2, 60% N.
Using 11-0 opthalmic suture, the arterioles were tied securely to micropipettes in a vessel
chamber (Living Systems, Inc., Burlington, VT) and filled with Krebs-Ringer
physiological saline solution (described above) containing 1% albumin (pH 7.4, 37°C)
(Pourageaud & De Mey, 1998). The bath was filled with Krebs-Ringer physiological
saline solution (pH 7.4, 37°C) and transferred to the stage of an inverted microscope
(Olympus (CKX41), Melville, NY). Luminal diameter was monitored during
equilibration and viability testing (described below) using video calipers (Colorado video
307A Horizontal video calipers, Boulder, CO) and recorded on a computer. The bath
was gradually warmed and maintained at 37°C for the equilibration period.
Micropipettes were connected to independent reservoir systems. Luminal pressure was
initially set at 60cm H2O, which is a pressure similar to normal in vivo pressure in 1A
arterioles (Williams & Segal, 1993). The bath solution was replaced every 15 minutes
during equilibration. Arterioles were considered viable if they constricted to
phenylephrine (10-5M) by at least 10% and dilated by at least 20% to acetylcholine (106

M ) (Schneider, et al., 1994). Maximum vasoconstriction (μm) was assessed by the

average vasoconstriction produced by potassium chloride (80mM) prior to, and
immediately following, that day's experiments. The arteriole was washed out 5 times,
and a calcium-free buffer was added to the bath to measure maximum arteriole dilation
(μm).
Field Stimulation. The arteriole was field stimulated using two platinum
electrodes connected to an electrically isolated, constant current stimulator (Digitimer
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(DS3), Welwyn Garden City, Hertfordshire, UK). In our lab’s experience, field
stimulation can be repeated up to four times without a loss of vascular tone.
Randomization. The following series described below were randomized to
minimize variability due time effects (i.e. the length of time the vessel is maintained in
the microvessel bath). The cumulative concentration response curves within Series 3
were randomized to reduce sequence effects.
Series 1: NPY release to field stimulation. The vessel received field stimulation
(60Hz, 9mA, 7 impulses), followed by extraluminal sampling (~200µl) immediately after
stimulation and 30 seconds post-stimulation. Samples were flash-frozen with liquid
nitrogen and stored at -80C. At the conclusion of the first set of experiments, the vessel
chamber was washed five times and allowed to equilibrate for 30 minutes before
proceeding to the next set of experiments.
Series 2: Y1 post-junctional receptor sensitivity. A cumulative concentration
response curve using the Y1 specific agonist, [Leu31Pro34]NPY (Bachem, King of
Prussia, PA), was performed (10-11-10-5M). Doses were administered at five minute
intervals. Data was expressed as a percentage of maximum contraction (µm), percentage
of baseline tension, EC50, and slope. Data were analyzed using EC50 and slope. At the
conclusion of the second set of experiments, the vessel chamber was washed five times
and allowed to equilibrate for 30 minutes before proceeding to the next set of
experiments to avoid possible residual effects from the previous experiment.
Series 3: NPY potentiation of adrenergic vasoconstriction. A cumulative
concentration response curve for the α-adrenoceptor agonist, norepinephrine (10-11-106

M), was performed to determine adrenergic responsiveness of the vessel. A

36

concentration of NPY(1-36) (10-7M) capable of eliciting potentiation of norepinephrine
vasoconstriction was added to the bath and allowed to incubate for five minutes. A
second cumulative concentration response curve for norepinephrine was performed to
examine the potentiation effect of NPY on adrenergic vasoconstriction. Data were
expressed as a percentage of maximum contraction (µm), percentage of baseline tension,
EC50, and slope. Data were analyzed using EC50 and slope. The vessel bath was
washed out and the arteriole allowed to equilibrate as described above.
Series 4: DPPIV activity in gastrocnemius first-order arterioles. The DPPIV
inhibitor, diprotin A (1μM), was added to the bath and allowed to incubate for 20
minutes. The arteriole received field stimulation (60Hz, 9mA, 7 impulses), which was
followed by extraluminal sampling (~200µl) immediately after stimulation and 30
seconds post-stimulation. Samples were flash-frozen with liquid nitrogen and stored at 80C. Upon completion of all animal experiments, samples were analyzed for NPY
content using a peptide enzyme immunoassay (Bachem, King of Prussia, PA).
Arterioles from the contralateral gastrocnemius were homogenized in KrebsRinger buffer, centrifuged, and the supernatant removed for DPPIV analysis. DPPIV
samples were flash-frozen with liquid nitrogen and stored at -80C. Upon completion of
all animal experiments, samples were analyzed for DPPIV and total protein content
(Thermo Scientific, Rockford, IL) using spectrophotometric assay. Serum concentrations
of 17β-estradiol were determined using an estradiol immunoassay (Estradiol EIA kit,
Oxford Biomedical, Oxford, MI).
Peptide enzyme immunoassay (EIA). Vessel bath samples and EIA kit
components were brought to room temperature before proceeding with NPY analysis.
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The samples were placed in an antibody-coated, 96-well plate with provided standards.
Primary antiserum and biotinylated peptide solutions were added and incubated for two
hours at room temperature. The samples were washed with an assay buffer and treated
with streptavidin HRP solution and incubated for 60 minutes at room temperature.
Following a second wash cycle, the substrate was added and the absorbance read at
450nm (Bio-Tek Instruments Inc., Winooski, VT). The concentration of NPY was
determined using a normal curve. The assay’s minimum detectable NPY concentration is
2 to 3 pg per well or 0.06ng/ml.
Dipeptidyl peptidase IV assay. Whole vessel homogenate samples were brought
to room temperature. The samples were then transferred to a 96-well plate and glycyl-Lproline-4-methoxy-2-naphthylamide added (37). The samples were incubated for 20
minutes at 37°C and the reaction stopped using a citrate solution (100mM). The
fluorescent signal was read at 340 and 425nm by a FLX800 microplate reader. DPPIV
activity was defined as the activity that produces 1μM of 4-methoxy-2-napthalamine in
one minute (Scharpe, et al., 1988).
Protein assay. Whole vessel homogenate samples were brought to room
temperature. Samples (150µl) were transferred to a 96-well plate along with a working
reagent (150 µl). The plate was placed on a heating block (37°C) and allowed to incubate
for 2 hours. The plate was removed from the heating block to equilibrate to room
temperature (~10min) before analysis. Absorbance of a colorimetric signal was read at
562nm. Total protein content (µg/ml) was determined using a bovine serum albumin
standard curve.
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17β-estradiol assay. The organic phase was separated by vortexing the sample
with ethyl ether. The solvent was evaporated using a nitrogen stream, and the remaining
residue was diluted in extraction buffer. This sample was added to the microplate along
with the enzyme conjugate, shaken, and incubated at room temperature for one hour.
Following a wash cycle, the substrate was added with optimal color development
(650nm) occurring within 30 minutes of administration. Color development was
inversely proportional to the concentration of estradiol.
Statistical Design
It is prudent to minimize the number of statistical tests in order to decrease type I
error rate. Therefore, data of similar formats (e.g. cumulative concentration response
curves and NPY release) were analyzed together when possible. A multivariate analysis
of variance (α=.05) was used to analyze the data from series 2 and 3. The EC50 and
slope were recorded for NPY, norepinephrine, and NPY+ norepinephrine cumulative
concentration response curves. A repeated measures design (α=.05) was used to assess
differences in data from series 1 and 4. NPY release (ng ml-1) with and without diprotin
A (dipeptidyl peptidase IV inhibitor) was recorded at 0 seconds and 30 seconds post-field
stimulation. Greenhouse-Geisser’s epsilon was used as the criterion (O'Rourke, Hatcher,
& Stepanski, 2005) for determining usage of either the univariate (ε > 0.75) or
multivariate (ε < 0.75) case, where appropriate. Dipeptidyl peptidase IV activity (second
part of series 4) was analyzed using a one-way analysis of variance design (α=.05).
In our lab, we have previously detected differences in NPY release from
gastrocnemius 1A arterioles. Based on our prior work, we needed at least 12 animals to
achieve power > .80 with α= .05 (Δ=1.83). Previous analysis of dipeptidyl peptidase IV
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activity in our lab did not include the vessel’s size in the determination of activity. It was
possible that total enzyme activity as determined by the amount of synthetic substrate
converted to measureable product was a function of vessel size (i.e. there was more
physical dipeptidyl peptidase IV protein in some experiments). Consequently, the
standard deviations were higher than desired, which for the present experiment, would
have required a larger group size (n=21) in order to reach our desired power (>.80).
Therefore, the protein assay was included in order to normalize the DPPIV activity with
respect to the vessel’s size (total protein content). Power calculations of subsequent
enzyme assay (monoamine oxidase) results using protein quantification to normalize
activity required a group size of 12 to meet a power of at least .80 with α= .05 (Δ=1.87).
NPY-mediated vasoconstriction increases in magnitude as vessel diameter decreases.
Joshua (1991) observed decreases of ~39±2% in first-order arteriole diameter following
NPY administration. This large effect yields a substantial degree of power (>.90). Based
on the aforementioned power calculations, this study utilized groups of 15 animals
(N=30), which was deemed sufficient to detect group differences with power > .80; α=
.05.
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RESULTS AND DISCUSSION
Results
Model assumptions for all statistical instruments were examined with follow-up
measures performed when necessary. Data considered essential for interpretation are
included in the results. Appendix A contains more detailed information regarding data
organization, inclusion criteria for statistical analysis, and the handling of model
assumptions.
A treatment duration of 8 weeks (56 days) was selected to allow for an adequate
amount of exposure time to estrogen in order to detect the presence of physiological
adaptations to chronic estrogen exposure. The average treatment time (from OVX/OVE
surgery to terminal experiment) was 55.76 ± 0.30 days, and the ages at the time of
terminal experiment ranged from 158 days to 224 days. The length of a terminal
experiment was 6 hours; thus, a maximum of two experiments could be performed on any
given day. The small variation in treatment duration was due, in part, to conflicts that
were either unavoidable or beyond control (meetings, equipment failure/damage). A total
of 35 rats were ovariectomized, while 17 rats also received the 17β-estradiol pellet. The
only death that occurred during the treatment phase was attributed to sodium
pentobarbital overdose. No rats exhibited signs or symptoms of surgical complications
during the 10-day post-surgical observations, and there were no signs of infection or
adverse conditions at the time of the terminal experiment.
Animal Characteristics
Plasma estrogen concentrations were greater in rats with estrogen
supplementation (OVE) as compared to rats without estrogen supplementation (OVX;
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Figure 4: F (1, 9) = 7.67, p < 0.05). The presence of estrogen can produce alterations in
phenotype that are readily observable and easy to measure. OVE exhibited less weight
gain over the 8-week period (Figure 5: F (1, 32) = 47.05, p < 0.05) but had substantially
larger uteri as opposed to OVX (Figure 6: F (1, 26) = 1812.17, p < 0.05). Figure 7
displays representative uteri from OVE (A and B) and OVX (C and D) rats. The
collective statistical effects of measurements related to estrogen supplementation were
high (plasma estrogen: d = 1.68; body weight: d = 2.35; uterine weight: d = 16.09).
These data suggest a significant difference in estrogen concentrations between OVE and
OVX rats.
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Figure 4. Plasma estradiol concentration of
OVX (n = 5) and OVE (n = 6) rats. Estrogen
supplementation resulted in an increase in plasma
estradiol levels. Bars indicate mean ± S.E.M.
* Significant difference from OVX (p < 0.05).
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Figure 5. Body weight of OVX (n = 17) and OVE
(n = 17) rats. Estrogen supplementation resulted in
significantly less body weight. Bars indicate mean ±
S.E.M. * Significant difference from OVX
(p < 0.05).
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Figure 6. Uterine weight of OVX (n = 14) and
OVE (n = 14) rats. Estrogen supplementation
resulted in significantly greater uterine weight. Bars
indicate mean ± S.E.M. * Significant difference from
OVX (p < 0.05).
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Figure 7. Representative uteri from OVE (A and B) and OVX (C and D) rats.
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Series 1: NPY release to field stimulation
Field stimulation at a high frequency is needed in order to facilitate the exocytosis
of large dense-cored vesicles within the sympathetic nerve terminal (Lundberg, Pernow,
Franco-Cereceda, & Rudehill, 1987). NPY release increased from 0 to 30 seconds in
OVX and OVE rats (Figure 8: F (1, 21) = 6.44, p < 0.05). While OVX (n = 12) rats
experienced slightly greater NPY release at 0 and 30 seconds, the release was not
statistically different (F (1, 21) = 0.05, p < 0.83, D2 = 0.05) from OVE (n = 11).
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Figure 8. NPY release in gastrocnemius first-order arterioles of OVX (n
= 12) and OVE (n = 11) rats. NPY release was greater at 30s following field
stimulation for all rats irrespective of estrogen status. Bars indicate mean ±
S.E.M. * Significant difference from 0s (p < 0.05).
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Series 2: Y1 post-junctional receptor sensitivity
This series was performed to determine the effects of long-term estrogen
supplementation on Y1-receptor activity in skeletal muscle arterioles. The Y1-receptor
agonist, [Leu31Pro34]NPY, elicited a 45% decrease in vessel diameter of skeletal muscle
arterioles. Estrogen status did not affect the maximum amount of Y1-mediated
vasoconstriction (F (1, 14) = 0.01, p = 0.91; d = 0.05) with OVE (55.07 ± 5.10%; n = 9)
producing similar magnitudes of vasoconstriction to that observed in OVX (55.97 ±
6.25%; n = 7). The sensitivity of Y1-receptor actions to cumulative concentrations of
[Leu31Pro34]NPY did not differ with respect to estrogen status (Figure 9: F (2, 13) =
0.84, p = 0.45; D2 = 0.46).
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Figure 9. Cumulative concentration response curve
for Y1 -receptor agonist. NPY-mediated
vasoconstriction was similar in OVX (n = 7) and OVE
(n = 9) rats. Bars indicate mean ± S.E.M.
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Series 3: NPY potentiation of adrenergic vasoconstriction
NPY potentiates norepinephrine-mediated vasoconstriction through Y1-receptor
activation. This series was performed to assess the effects of estrogen on this Y1dependent mechanism. OVE (n = 12) did not differ from OVX (n = 13) in
norepinephrine-stimulated vasoconstriction (Figure 10: F (2, 22) = 0.19, p = 0.83; D2 =
0.06). Interestingly, neither OVE (n = 11) nor OVX (n = 10) exhibited NPY potentiation
of norepinephrine-stimulated vasoconstriction (Figures 11: F (2, 18) = 1.23, p = 0.32; D2
= 0.49).
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Figure 10. Cumulative concentration response
curve for α-adrenergic-receptor agonist.
Norepinephrine-mediated vasoconstriction was similar
in OVX (n = 13) and OVE (n = 12) rats. Bars indicate
mean ± S.E.M.
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Figure 11. Cumulative concentration response
curve for NPY ([Leu31Pro34]NPY) potentiation of
α-adrenergic-receptor agonist in OVX (A: n = 10)
and OVE rats (B: n = 11). NPY failed to potentiate
norepinephrine-mediated vasoconstriction in OVX and
OVE rats. Bars indicate mean ± S.E.M.
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Series 4: DPPIV activity in gastrocnemius first-order arterioles
The enzymatic breakdown of NPY can impact the physiological response as only
the full-length peptide stimulates vasoconstriction. The DPPIV inhibitor, diprotin A, was
added to the vessel bath to determine the effects of DPPIV activity on NPY
bioavailability according to estrogen status. DPPIV inhibition resulted in an increase in
NPY bioavailability at 0s and 30s following field stimulation in OVX (n = 12) and OVE
(n = 11) rats (Figure 12; F (3, 19) = 4.74, p < 0.05); however, there were no differences
across groups (F (3, 19) = 1.10, p = 0.37, D2 = 0.74).
Whole vessel homogenates were analyzed to directly assess DPPIV activity.
DPPIV activity (Figure 13: F (1, 26) = 0.01, p = 0.94, d = 0.03) did not differ between
OVX (n = 13) and OVE rats (n = 15). Follow-up protein assay was unable to determine
differences in total vascular protein of OVX (n = 9) and OVE (n = 9) vessels (see
Limitations). DPPIV activity was similar between groups and the proteolytic actions of
DPPIV played an integral role in modulating the bioavailability of NPY regardless of
estrogen status in this young-adult cohort.
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Figure 12. Effects of DPPIV inhibition on NPY release in gastrocnemius
first-order arterioles of OVX (n = 12) and OVE (n = 11) rats. NPY
release was greater with DPPIV inhibition (diprotin A) at 0s and 30s
following field stimulation for all rats regardless of estrogen status. Bars
indicate mean ± S.E.M. * Significant difference from control conditions (0s
and 30s, respectively; p < 0.05).
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Figure 13. DPPIV activity of OVX (n = 13) and
OVE (n = 15) first-order arterioles. Estrogen
supplementation did not influence DPPIV activity.
Bars indicate mean ± S.E.M.
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Discussion
NPY Vasoconstriction
The efficacy of NPY as a vasoconstrictor depends on the level (artery, arteriole)
and location (mesentery, brain, skeletal muscle) of the vasculature under study. Very
little is known as to the behavior of NPY in the skeletal muscle arterioles of females.
Prior study (Joshua, 1991) of male skeletal muscle arterioles revealed an inverse
relationship between the magnitude of vasoconstriction (vessel diameter changes) and
vessel size (first-, second-, third-order arterioles). The amount of vasoconstriction
observed in female skeletal muscle first-order arterioles was similar to previous
measurements of the same vessel type observed in males (Joshua, 1991). The
cornerstone of the study was the long-term effect of estrogen on NPY neurotransmission.
The available studies on sex-differences (Jackson, et al., 2005a, 2005b) in NPY
neurotransmission have suggested that sex hormone status is a likely cause underlying the
differences between males and females. The present data fail to support a link with
respect to estrogen and Y1-receptor activity as there were no differences between OVX
and OVE groups. While the null hypothesis was not rejected, the results further
demonstrate the complexities involved in identifying the factors of influence behind the
sex-differences in vascular physiology.
An absence of an estrogen effect is not unprecedented with similar null results
having been observed in adrenergic neurotransmission. Stice et al. (2009) observed no
differences in adrenergic responsiveness in female aortas of OVE and OVX rats. The
aortas of rats without estrogen possessed greater contractile force (developed tension)
than rats with estrogen, but the receptor responsiveness according to the adrenergic dose-
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response curve did not differ between groups. Females with compromised estrogen
profiles may experience vascular smooth muscle thickening (Moreau, et al., 2002;
Takahashi, et al., 2004), which is a common clinical sign for increased risk of
cardiovascular disease. The nature of microvessel diameter measurement does not allow
for an inference as to the amount of contractile force a vessel possesses; therefore, it was
unknown if OVX vessels possessed greater contractile force. Y1-receptor protein was not
quantified during the present study; thus, it is unknown if either of the groups
experienced a change in receptor protein with a concurrent change in receptor sensitivity.
A recent study by Jackson, Ellis, and Shoemaker (2010) detected estrogen-related
differences in Y1-receptor expression in white vastus muscle of young mature (2mo)
female rats. The increase in post-junctional receptor expression in rats without estrogen
was in conjunction with changes in hemodynamics of conduit vessels (external iliac
artery) in response to Y1-receptor blockade. However, there was a nonsignificant
increase in Y1-receptor in red vastus of rats with estrogen. These equivocal results may
suggest that differences in Y1-receptor actions may occur in response to changes in
estrogen status, but these changes may be predicated on the type of muscle (red or white)
tissue and corresponding blood vessels under study. The present results would support a
part of this concept in that Y1-receptor actions were identical in the red first-order
arterioles of young adult females irrespective of estrogen status. It was concluded that
NPY can induce a moderate amount of vasoconstriction in isolated first-order arterioles
of young adult females, and estrogen does not impact Y1-receptor sensitivity in these
vessels.
NPY Potentiation of Adrenergic Vasoconstriction
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Neuropeptide Y is well known for its ability to potentiate norepinephrine-induced
vasoconstriction at low concentrations (10-7 – 10-9 M) (Abel & Han, 1989; Han, et al.,
1998; Vu, et al., 1989). The type of potentiation can refer to augmentation of the
vascular response (vasoconstriction, increases in perfusion pressure) achieved following a
neural stimulus (Glenn & Duckles, 1994; Han, et al., 1998), or it can refer to a leftward
shift in the dose-response curve of norepinephrine indicating a greater sensitivity to
norepinephrine (Abel & Han, 1989). The ability of NPY to potentiate any facet of
adrenergic vasoconstriction may depend on other factors such as vessel type and sex. In
the present study, OVX and OVE groups experienced a nonsignificant increase to
norepinephrine-mediated vasoconstriction following NPY administration. The
concentration used, 9.8 X 10-8 M, is within the previously mentioned range of
concentrations where NPY potentiates norepinephrine-mediated vasoconstriction.
However, the vessels of both groups exhibited vasoconstriction to this concentration of
NPY, which could have masked minor influences on adrenergic vasoconstriction.
There are many examples of NPY potentiation of norepinephrine effects on
perfusion pressure of whole systems such as the mesentery (Han, et al., 1998; Westfall, et
al., 1988). Arterial beds provide a story as to a particular vascular system. However, the
potentiation cannot be accurately ascribed to any particular level within the system since
the pressure changes represent a collective response to the stimulus (norepinephrine,
norepinephrine + NPY). Isolated vessel techniques circumvent the aggregate actions of
whole vascular beds to allow for careful examination at specific levels of the vasculature.
Thus, while potentiation may occur in some levels of the vasculature, it does not appear
to occur in skeletal muscle first-order arterioles.
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The existence of multiple pathways for NPY-mediated vasoconstriction may
explain the lack of potentiation in norepinephrine vasoconstriction. NPY can influence
both potassium and calcium flux via the inhibition of cAMP (Lobaugh & Blackshear,
1990) and the production of IP3 (Duckles & Buxton, 1994), respectively. Norepinephrine
stimulates vasoconstriction through the production of IP3; therefore, the absence of NPY
potentiation of norepinephrine would support the assertion that NPY does not cause a
meaningful increase of IP3 in skeletal muscle arterioles. This is consistent with other
studies of arterioles that failed to observe a difference in vasoconstriction following the
inhibition of cAMP production (Andriantsitohaina, et al., 1990). It is certainly possible
that the ability of NPY to potentiate the effect of norepinephrine is dependent on vessel
size as some larger vessels experience increases in IP3 production following NPY
administration (Duckles & Buxton, 1994). It was surmised based on the present results
that the cAMP inhibitory mechanism is the predominant mechanism through which NPYmediated vasoconstriction occurs in skeletal muscle arterioles of females, and that NPY
does not elicit a meaningful amount of IP3 production to potentiate the vasoconstriction
of norepinephrine. The similarity of response to NPY in animals with and without
estrogen suggests that the Y1-receptor mechanism was not influenced by estrogen
supplementation. NPY was a potent vasoconstrictor of skeletal muscle arterioles in both
groups, but it does not affect the vascular response to norepinephrine.
NPY Release
There is little information, if any, pertaining to NPY release from skeletal muscle
arterioles. Previous studies of whole skeletal muscle and conduit arteries have detected
sex differences in total NPY content of the respective tissues. It has been speculated that
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estrogen could contribute to a portion of the differences observed between males and
females. In the present study, chronic estrogen supplementation did not affect NPY
release at 0 or 30 seconds following field stimulation. These data suggest that chronic
estrogen does not influence NPY release in skeletal muscle first-order arterioles of young
adult females.
Estrogen affects the expression of many vascular proteins (Miller & Duckles,
2008); therefore, it was plausible that estrogen was an underlying mechanism behind the
sex differences observed in total NPY content of various tissues. A follow-up study into
the effects of estrogen supplementation on NPY metabolism by Jackson et al. (2010)
concluded that rats with estrogen had less NPY content in red and white vastus muscles.
The differing results between the present study and the study by Jackson et al. could be
attributed to several factors. First, whole muscle homogenate does not discriminate
between vessel type (arteries, veins, capillaries, venues); thus, it is difficult to pin down
the source behind the differences in NPY content. Whole muscle homogenate will also
include blood elements that contain NPY originating from monaural sources (platelets,
adrenal gland). These sources may be sensitive to estrogen supplementation, which could
affect the expression of NPY. The present study possesses experimental control for
extraneous sources of NPY such as those related to blood elements. Therefore, the NPY
content recorded is indicative of the NPY release characteristic of an isolated, skeletal
muscle first-order arteriole, which appears to be independent of estrogen influence.
While this study was not directly concerned with age, age-related physiological
issues in females often encompass dysfunctional release of sex steroids. Recent work by
Di Carlo et al. (2007) discovered increases in NPY content of human uterine arteries that
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correlated with the different phases of menopause (pre- and post-menopause). These data
require a broader context for interpretation as other hormones (progesterone) may also
influence vascular NPY content. Ageing, as it relates to vascular physiology, also affects
multiple aspects of the vasculature that involve alterations in function to both the
endothelium and the vascular smooth muscle (Glenn & Duckles, 1994; Kitlinska, Lee,
Movafagh, Pons, & Zukowska, 2002). The present finding indicates that estrogen, in and
of itself, does not contribute to a change in NPY release in isolated, skeletal muscle firstorder arterioles.
DPPIV Activity
The actions of DPPIV can significantly impact the type and magnitude of
response initiated by NPY. Glenn et al. (1997) was one of the first to detect differences
in vasoconstriction during peptidase inhibition between sham and ovariectomized
females. An elegant study by Jackson et al. (2005) proposed that females possessed a
greater level of proteolytic activity than males in order to depress Y1-receptor-mediated
vasoconstriction. Thus, the hypothesis for estrogen’s involvement in the attenuation of
NPY-mediated vasoconstriction was developed. The present findings fail to support a
link between estrogen and NPY metabolism in skeletal muscle arterioles. While no effect
was observed with estrogen supplementation, the results do reveal some interesting
developments in our concept of NPY in the vasculature.
DPPIV activity plays a significant role in mitigating NPY availability in
resistance vessels of young adult females regardless of estrogen status. The physiological
significance of an augmented role for DPPIV in the female resistance vasculature is that
females would have less Y1-receptor actions, ergo less NPY-mediated vasoconstriction.
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Systemic blood pressure is maintained, in part, through the actions of arterioles, which
control blood flow into the capillary beds (Segal, 2005). While it is difficult to determine
the meaningfulness of DPPIV activity in influencing blood flow through the resistance
vasculature, the present results do suggest a significant role for DPPIV in modulating the
amount of available NPY.
The stark similarities of DPPIV activity through direct (enzymatic assay) and
indirect (NPY assay following DPPIV inhibition) measurements provide evidence to
support the idea that estrogen does not affect DPPIV mechanisms in first-order arterioles.
Jackson et al. (2010) detected no difference in DPPIV activity with estrogen
supplementation in whole tissue homogenate of red and white vastus muscles. The
strength of the present study was the DPPIV analysis of isolated first-order arterioles.
Thus, DPPIV activity is independent of estrogen influences, and it is active in modulating
NPY in first-order arterioles of young adult females.
Practical Implications
The release and metabolism of NPY can have far reaching effects; thus, it is
prudent to understand how and under what circumstances these mechanisms associated
with NPY metabolism change in the vasculature. A practical concern relevant to
cardiovascular health is the increase in blood pressure that accompanies the ageing
process (Narkiewicz, et al., 2005; Ng, Callister, Johnson, & Seals, 1993). This is a
multifaceted issue consisting of alterations in neurotransmitter release, receptor
expression on the vascular smooth muscle, vascular smooth muscle cell proliferation, and
endothelial cell function, to name a few. The estrogen-independent conclusions of the
present study are not unprecedented. Stice et al. (2009) failed to detect estrogen-related
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differences in adrenergic vasoconstriction; however, there were differences with age.
Aged females were more sensitive to adrenergic agonists (phenylephrine) as compared to
young adult females irrespective of estrogen status. It should be noted that both young
and old females without estrogen generated greater amounts of tension as compared to
young and old females without estrogen. A greater amount of vascular tension can be a
function of vascular smooth muscle cell proliferation. As stated above, vessel tension
cannot be extrapolated from vessel diameter. The inability to measure vessel tension
along with the inconclusive measurements of total vascular protein makes it difficult to
ascertain whether estrogen status influenced vascular smooth cell growth in the present
study. It is plausible, however, that estrogen-related differences in blood pressure with
age are actually a product of small increases in vascular smooth muscle cell proliferation
as opposed to increases in receptor actions of sympathetic neurotransmitters such as
NPY.
Correlations between NPY content and menopause status have been observed in
human uterine arteries. Menopause marks an onset of dysfunctional release of sex
steroids (estrogen, progestogen). It is because of these interrelationships that sex
steroids, specifically estrogen, are believed to be crucial in modulating NPY metabolism.
The absence of an estrogen effect in the present study would run counter to an estrogenspecific response on NPY metabolism. Perhaps the previous relationships between
hypoestrogenism and NPY content is dependent on progesterone or possibly on
synergistic effects requiring both sex steroids. Another caveat in the study of sex steroid
influence in ‘intact’ females lies in the enzymatic milieu and form of estrogen present.
Some vascular smooth muscle cells express steroid enzymes such as sulfatases and

64

sulfotransferases, which affect the amount of estrogen in conjugated form (Nakamura, et
al., 2003). These enzymes in addition to 17β-hydroxysteroid dehydrogenase-1 can affect
the overall estrogen profile. This profile necessitates careful consideration due to the
variable potency of the different forms (estrone, estradiol) of estrogen in the vasculature.
It is important to elucidate the underlying mechanisms behind menopause and NPY
expression to expand our knowledge into factors related to ageing in females.
NPY is also an angiogenic peptide (Zukowska-Grojec, et al., 1998) with growth
factor capabilities that are equivalent to that seen with vascular endothelial growth factor
under certain conditions (Kurimoto, et al., 2004). The angiogenic form of NPY is
primarily associated with its fragmented metabolites that express an affinity for Y2 and
Y5 receptors, although the Y1 receptor also initiates angiogenic mechanisms as well
(Movafagh, Hobson, Spiegel, Kleinman, & Zukowska, 2006). Since DPPIV produces
these truncated forms of NPY (NPY3-36), increased activity of this enzyme at the local
vascular level could produce pro-angiogenic processes. Therefore, DPPIV has a dual role
in NPY metabolism by decreasing the amount of vasoconstrictive NPY while
concurrently increasing the amount of pro-angiogenic NPY. This action could result in
both beneficial and deleterious health effects. On one hand, this function could serve to
improve overall cardiovascular function by increasing the number of collateral branches
from arterioles through angiogenesis and decreasing the amount of vasoconstriction via
NPY mechanisms. However, as a growth factor, increased proliferation of vascular
smooth muscle cells could lead to changes in the tunica intima/media ratio under certain
conditions, which is a risk factor for cardiovascular event.
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NPY and estrogen both possess pleiotropic actions in the vasculature. It is this
nature that necessitates thorough analysis from multiple angles in order to piece together
possible interrelationships between NPY and estrogen. Future studies should include
progesterone supplementation in combination with estrogen to better mimic in vivo
conditions, which would allow for the identification of possible synergistic effects
between hormones. Studies that include peptide/hormone expression (transcripts,
prepro/prohormone) in addition to receptor expression along with subtypes would allow
for a more comprehensive picture into sex steroid influences on NPY neurotransmission.
Caveats
Ovariectomy of all animals was necessary to ensure experimental control over
estrogen concentrations. Surgery and long-term storage can create stress on the animals,
which could affect normal physiology. NPY release was elevated in both groups as
compared to intact animals of the same age (unpublished data). Therefore, caution
should be used when comparing results from the present study to those found in intact
females.
The age of animal selected (6 months) represents a young adult female (Turturro,
et al., 1999). While this was not an ageing study, some of the research into sex steroids
and sympathetic neurotransmission utilize multiple age groups. The present results
suggest that long-term estrogen supplementation does not affect NPY release and
degradation in young adult females. However, the process of ageing may involve other
mechanisms that, combined with estrogen, produce alterations in NPY metabolism that
have been observed in other studies (Glenn & Duckles, 1994).
Conclusions
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Long-term estrogen supplementation does not affect NPY metabolism in young
adult females. The Y1-receptor actions are uniform across estrogen and non-estrogen
groups with maximal vasoconstriction approximately 55% of control diameter in skeletal
muscle first-order arterioles. Estrogen supplementation did not influence NPY release or
DPPIV activity. DPPIV plays an important role in attenuating the amount of bioavailable
NPY in young adult females.
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APPENDIX
Data Analysis
The initial dissertation proposal called for a total of 30 rats (15 / group). A total
of 34 rats underwent surgery with half of those receiving the estrogen treatment. While
there were a sufficient number of animals for experimental purposes, not all of the
animals were used in each experiment. Reasons for animal exclusion on some
experiments included equipment failure due to lab damage, drug costs (limited
availability), and issues with vessel viability (for microvessel experiments). Information
relevant to specific series of experiments are listed below.
Model assumptions (α = 0.05) for both the univariate and multivariate case were
considered for the respective statistical comparisons. The assumption pertaining to
independence of observations was addressed through uniform handling and storage of the
animals. Briefly, the animals were of the same strain (Fischer 344 rats) and were
purchased from the same provider. Animals were housed under 12:12 hour light:dark
cycles, housed in the same facility and room, and consumed the same diet.
Ovariectomized (OVX) and ovariectomized + estrogen (OVE) animals shared cages in
order to minimize the possibility of ‘cage’ effects. The previous steps were performed to
ensure biological homogeneity with the exception being sex steroid profile, which was
manipulated for experimental purposes.
Simple univariate descriptive statistics pertaining to distribution (Shapiro-Wilk,
skewness, kurtosis) are provided for each dependent variable in addition to graphical
representation (box-and-whisker plots). The following sections provide information
regarding the handling of data with regards to adherence to specific model assumptions.
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Animal Characteristics
Plasma estradiol concentration. Plasma estradiol was assayed for 11 rats
(Figure A1: OVE [n = 6], OVX [n = 5]). Estradiol was normally distributed (Table A1),
and the variances were equal.
Body weight. A total of 34 rats were ovariectomized with 17 rats receiving the
estrogen treatment (Figure A2). The body weights were normally distributed (Table A2),
and the variances were equal.
Uterine weight. The uterine weights were measured for all 34 rats. The
normality assumption did not hold due to a few extreme scores in an otherwise narrow
distribution. These extreme scores in both groups were attributed to surgical differences
across rats. Ovariectomy involves the removal of the ovaries, which requires two sutures
for each ovary: one at the uterine horn and one at the adipose tissue on the other side of
the uterine horn. The uterine horn and ovary possess a significant amount of adiposity
with a high degree of vascular supply to address. Small openings are made in the
surrounding adipose tissue to allow for careful suture of the uterine horn only with
minimal adipose tissue involved. A minimal amount of adipose tissue is desired when
suturing as all tissue distal to the suture will become necrotic, so care is taken to prevent
excessive amounts of necrosis. All rats have varying amounts of fat to deal with in and
around the reproductive organs, which influences the specific location of the suture
around the ovary. These small differences in suture location can affect the overall length
of the uterine horn. It was concluded that the small differences in suture location were
responsible for the outliers seen in both groups, which caused the deviation away from a
normal distribution. Animals that comprised the outliers were removed from both groups
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(OVX: # 22 (274 mg), # 27 (258 mg); OVE: # 2 (1330 mg), # 6 (1204 mg), # 12 (1174
mg). This addressed the normality assumption (Figure A3), but variances were not equal.
In looking at the data and the magnitude of change in uterine weight with estrogen, it
came as no surprise that the variances were not equal. A decision was made to randomly
select an observation from the group with the most observations (OVX: rat #31) and
remove it from statistical consideration (Glass & Hopkins, 1996). This step produced
equal group sizes, which resulted in an analysis that was robust to the homogeneity of
variances assumption (Glass & Hopkins, 1996).
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Table A1
Univariate Normality: Descriptive Statistics
Variable
Statistic
Plasma Estradiol Concentration
Skewness
Kurtosis
Shapiro-Wilk
Body Weight
Skewness
Kurtosis
Shapiro-Wilk
Uterine Weight
Skewness
Kurtosis
Shapiro-Wilk
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OVE

OVX

1.20
1.30
0.91

1.28
2.89
0.84

-0.50
-0.55
0.96

0.11
0.03
0.99

-0.13
-1.01
0.94

0.60
-0.60
0.93

Estradiol (pg ml -1)

40
30
20
10
0
OVX

OVE

Figure A1. Plasma estradiol concentration boxand-whisker plots for OVX (n = 5) and OVE (n =
6) rats.
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Body Weight (g)

280
260
240
220
200
180
160
OVX

OVE

Figure A2. Body weight box-and-whisker plots for
OVX (n = 17) and OVE (n = 17) rats.
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Uterine Weight (mg)

1400
1200
1000
800
300
200
100
0
OVX

OVE

Figure A3. Uterine weight box-and-whisker plots
for OVX (n = 14) and OVE (n = 14) rats.
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Cumulative Concentration Response Curves
The drug used to assess the activity of NPY’s post-junctional receptor, [Leu31Pro34]NPY, was in limited supply do to cost. Therefore, a limited number of animals (N
= 19) underwent cumulative concentration response curve testing for NPY with some
observations excluded post hoc for various reasons (listed below). The omnibus
multivariate analysis of variance (F (6, 9) = 1.39, p = 0.32, D2 = 3.29) for the cumulative
concentration response curves considered only complete observations, that is to say, only
the observations that included the [Leu31Pro34]NPY experiments. Since the omnibus
MANOVA consisted of a low number of observations, post hoc MANOVAs were
performed to include the observations where only norepinephrine or norepinephrine +
NPY (NPY potentiation) curves were performed.
MANOVA requires similar assumptions to those associated with the univariate
case. Independence of observations was discussed above, which leaves the assumptions
of multivariate normality and homogeneity of covariances to address. Univariate
normality does not ensure multivariate normality, but it is considered as a prerequisite for
multivariate normality (Stevens, 2002). Therefore, univariate normality was assessed for
all observations. While multivariate normality is an assumption for multivariate
ANOVA, the effect on the alpha level for violation of this assumption may be negligible
(Stevens, 2002). The likelihood for violation of the homogeneity of covariances
assumption increases with the number of variables included in the design. However, the
effects on alpha level with violations of this assumption are tempered when group sizes
are similar (large to small: < 1.5) (Stevens, 2002).
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A cursory examination of the data revealed the presence of two influential
outliers. In the case of rat #16 (OVE), the vessel responded in an atypical fashion.
Specifically, vasoconstriction following NPY or norepinephrine administration occurred
at one concentration, which yielded high slope values. This atypical response did not
exclude the data by itself as there is always variability between vessels during dose
response curves. However, there were factors associated with the experimental
preparation of this particular vessel that required consideration when interpreting the
data. Many of the vessels will have one or more collateral vessels, vessels that branch off
of the arteriole, which require a suture in order to pressurize the vessel for experimental
use. Suturing the vessel is a trial-and-error process with additional sutures needed if
leaks are detected during the equilibration period. Moreover, the amount of branching
differs between vessels, so some vessels require a great deal of attention (more sutures)
during the preparatory phase of microvessel experimentation. The vessel for rat #16
required many sutures as there were many collateral branches to tie off. Unfortunately,
there were a number of leaks discovered during equilibration of this vessel, and the
collateral branches were in a position that made tie-off difficult. The leaks were
successfully sutured, but the vessel was physically manipulated to a point where normal
vascular response could have been compromised. Following careful observation and
consideration of the NPY and norepinephrine data, it was decided that this outlier
occurred due to excessive manipulation of the vessel during experimentation. The
cumulative concentration response curve data from rat #16 was removed from analysis.
The second outlier, rat #19 (OVX), had abnormally low resting vessel diameter values. It
was noted in the procedural notes that there were a number of bubbles present in the tips
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of the vessel. Bubbles near the entry ports of the vessel can interfere with the flow of
albumin through the vessel. This causes the vessel to collapse to a certain extent, which
may potentially confound measurements of vascular response that utilize vessel diameter
as the dependent variable. As the percent of resting baseline values for this animal
influenced the normal distribution of NPY and norepinephrine cumulative concentration
response curves, it was decided that this outlier also occurred as a result of experimental
manipulation and the data was subsequently removed from analysis (Table A2).
NPY cumulative concentration response curve. The EC50 for rat #24 (OVE)
was an outlier. Graphpad software was able to obtain the curve fit; however, the curve
possessed two concentrations that exhibited substantial responsiveness to NPY. It was
decided that a manual curve fit would capture a more accurate representation of the actual
response to the drug, which in fact was the case (Graphpad fit: R2 = 0.97; manual fit: R2 =
0.98). The manual fit corrected the outlier, which produced a normal univariate
distribution (Figure A4) for the EC50. Rat #23 (OVE) failed to meet inclusion criteria
(R2 > 0.90) and was summarily removed from analysis. NPY slope (Figure A5) was
normally distributed, and univariate variances were equal for EC50 and slope.
Norepinephrine cumulative concentration response curve. The EC50 for
norepinephrine was normally distributed for both groups (Figure A6). The slope for
OVE was normally distributed, but the slope for OVX failed to exhibit a normal
distribution (Figure A7). All observations were left in the analysis as no justification
existed to warrant removal.
Norepinephrine + NPY cumulative concentration response curve. EC50 for
norepinephrine + NPY possessed a normal distribution for both groups (Figure A8).
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Slope was normally distributed for OVX, but not for OVE (Figure A9). Rat #14 (OVE)
had a steep slope (outlier), but there was not sufficient evidence to remove it from
analysis. OVX rats #1, Blank, and 1B along with OVE rat # 2 did not undergo
norepinephrine + NPY testing due to a shortage of [Leu31Pro34]NPY.
Effect sizes: meaningfulness of the differences. The multivariate effect size for
the omnibus MANOVA was large (D2 = 3.29), albeit statistically insignificant. The
omnibus MANOVA lacked power (< 0.80) to detect statistically significant differences
due to the large number of dependent variables with a relatively small number of
observations. While the large effect size was intriguing, the post hoc MANOVAs for
each drug (EC50 and slope), however, failed to further expose differences between the
groups. The moderate effect sizes observed in the NPY (D2 = 0.46) and NPY +
norepinephrine (D2 = 0.46) cumulative concentration response curves would necessitate
group sizes of approximately 40-50 observations to achieve reasonable statistical power
(> 0.80) (Stevens, 2002). The post hoc MANOVAs coupled with the graphical
representation suggested that the groups were the same over the three cumulative
concentration response curves.
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Table A2
Univariate Normality: Descriptive Statistics
Variable
Statistic
NPY CCRC
EC50
Skewness
Kurtosis
Shapiro-Wilk
Slope
Skewness
Kurtosis
Shapiro-Wilk
NE CCRC
EC50
Skewness
Kurtosis
Shapiro-Wilk
Slope
Skewness
Kurtosis
Shapiro-Wilk
NPY+NE CCRC
EC50
Skewness
Kurtosis
Shapiro-Wilk
Slope
Skewness
Kurtosis
Shapiro-Wilk
*p < 0.05.
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OVE

OVX

-1.01
-0.06
0.88

0.59
-1.32
0.89

-0.35
-1.37
0.93

-0.20
-0.96
0.97

-0.70
-0.90
0.89

-0.64
-0.25
0.92

-0.57
-0.93
0.90

-0.55
-1.55
0.83 *

-1.08
0.97
0.90

-0.28
-1.63
0.89

-1.73
3.12
0.80 *

-0.94
-0.42
0.86

Log M [Leu31,Pro34]NPY

OVX

OVE

-4
-6
-8
-10
-12

Figure A4. N PY EC50 box-and-whisker plots for
OVX (n = 7) and OVE (n = 9) rats.
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% Baseline /
log M [Leu31,Pro34]NPY

OVX

OVE

0
-2
-4
-6
-8

Figure A5. NPY slope box-and-whisker plots for
OVX (n = 7) and OVE (n = 9) rats.
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OVX

OVE

Log M Norepinephrine

-4
-6
-8
-10
-12

Figure A6. Norepinephrine EC50 box-andwhisker plots for OVX (n = 13) and OVE (n = 12)
rats.
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OVX

OVE

% Baseline / log M NE

0
-2
-4
-6
-8

Figure A7. Norepinephrine slope box-and-whisker
plots for OVX (n = 13) and OVE (n = 12) rats.
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OVX

OVE

Log M Norepinephrine

-4
-6
-8
-10
-12

Figure A8. Norepinephrine + NPY EC50 box-andwhisker plots for OVX (n = 10) and OVE (n = 11)
rats.
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OVX

OVE

% Baseline / log M NE

0
-2
-4
-6
-8

Figure A9. Norepinephrine + NPY slope box-andwhisker plots for OVX (n = 10) and OVE (n = 11)
rats.
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NPY Release
A repeated measures design was used for the NPY release data. The univariate
case is a more powerful design when group sizes are small (Park, Cho, & Ki, 2009), and
the assumptions are similar to the previous univariate assumptions with the exception of
sphericity. There will be some degree of violation of the sphericity assumption as it is a
repeated measures design; thus, it would be expected to find correlations between
dependent variables. Severe violations can lead to inflated F values, and possibly,
spurious conclusions. Therefore, the Greenhouse-Geisser adjusted F-test was used to
protect against type-I error.
It was noted during casual observation of the data that NPY release of both OVX
and OVE groups was much higher than those observed in intact animals. The
significance of the high concentrations of NPY was that the assay had a maximum range
of 10 ng ml-1, and the assay was most sensitive around 1 ng ml-1. Some animals that were
otherwise normal possessed NPY concentrations that were beyond the detectable range of
the assay. It was speculated that the higher concentrations of NPY were a product of the
surgical procedure, long-term storage of the animals, or a combination of both.
Albino rats develop a reddish or pink appearance around their posterior neck and
back during long-term storage. It is believed that this color is associated with stress,
which can be attributed to the close-quarters storage of the animals. This coloring was
not excessive, and there were no signs of abnormal behavior. Animals were never kept in
seclusion except following surgery (< 2 days), and the cage size was within acceptable
guidelines for animals of this particular size. Nevertheless, long-term storage could have
played a role in the high NPY concentrations in both groups. Another cause of the high
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NPY concentrations could be due to the surgical procedure itself. Surgery creates a stress
on animals; thus, it would be plausible that a portion of the results were a product of the
surgical procedure. In either case, all animals received the same treatment, which
preserved the veracity of the group comparisons. However, some animals were excluded
based off of NPY concentrations that exceeded the assay’s concentration range, or in
cases where the vessel failed preliminary viability testing.
NPY release (Table A3) was normally distributed for OVX for all time points
except the first (0 seconds). OVX data (Figure A10) exhibited a tendency towards
positive skewness with a flat distribution with the exception of the 3rd time point (0
seconds with DPPIV inhibition), which was leptokurtic. None of the measures of
skewness or kurtosis were considered severe (> 2). OVE data (Figure A11) failed to
exhibit a normal distribution for the control time points (0 and 30 seconds) as well as the
first time point with DPPIV inhibition (0 seconds). The distributions consisted of a few
outliers that positively skewed the mean. Another feature of the OVE data was the
narrow distribution, especially with the control time points. Rats #13 and #15 were
responsible for the high degree of skewness observed in the OVE group. However, there
was nothing about these observations or animal characteristics that merited their removal
from the analysis. It was decided, based off a lack of evidence to justify their exclusion,
that the observations from rats #13 and #15 should remain in the analysis.
Similar to the cumulative concentration response curves, there was insufficient
power to detect statistically significant differences in NPY release between the groups. It
would require approximately 35-45 observations per group in order to possess reasonable
statistical power (> 0.80) to detect true differences in NPY release (Stevens, 2002) with
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the magnitude of effect present (D2 = 0.74). While statistical power was limited in this
analysis, the present results do not support a difference in NPY release with respect to
estrogen status.
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Table A3
Univariate Normality: Descriptive Statistics
Variable
Statistic
0 Seconds (Control)
Skewness
Kurtosis
Shapiro-Wilk
30 Seconds (Control)
Skewness
Kurtosis
Shapiro-Wilk
0 Seconds (DPPIV Inhibition)
Skewness
Kurtosis
Shapiro-Wilk
30 Seconds (DPPIV Inhibition)
Skewness
Kurtosis
Shapiro-Wilk
*p < 0.05.
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OVE

OVX

2.14
4.08
0.66 *

1.03
-0.06
0.85 *

1.50
3.08
0.83 *

0.16
-1.29
0.92

0.94
-0.28
0.85 *

1.33
1.56
0.86

0.60
-0.98
0.89

0.28
-1.32
0.90

NPY Release (ng ml -1)

8
6
4
2
0
0s

30s

0s

30s

DPPIV Inhibitor

Figure A10. NPY release box-and-whisker plots at
control and DPPIV inhibition conditions (OVX: n
= 12)
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NPY Release (ng ml -1)

8
6
4
2
0
0s

30s

0s

30s

DPPIV Inhibitor

Figure A11. NPY release box-and-whisker plots at
control and DPPIV inhibition conditions (OVE: n
= 11)
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DPPIV Activity
Differences in DPPIV activity were assessed through one-way analysis of
variance. OVE and OVX were similar in distribution (Figure A12); however, the OVX
group possessed two outliers, which adversely affected normality. Rats #1 and Blank
registered substantially lower DPPIV values as compared to the other rats within the
group. These differences were attributed to the homogenate composition (saline) of the
first two samples, which likely influenced the catalytic rate of the enzyme. These two
observations were removed from analysis yielding normal distributions (Table A4) and
equal variances.
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Table A4
Univariate Normality: Descriptive Statistics
Variable
Statistic
DPPIV Activity
Skewness
Kurtosis
Shapiro-Wilk
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OVE

OVX

-0.43
0.06
0.97

0.60
0.11
0.96

DPPIV Activity (U L-1 )

24
22
20
18
16
OVX

OVE

Figure A12. DPPIV activity of whole vessel
homogenate (first-order arteriole) box-andwhisker plots for OVX (n = 13)and OVE (n = 15)
rats.
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